TrialJournal of thrombosis and thrombolysis2021

Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction.

Mohamed Abo-Aly et al.PubMed ↗Publisher ↗

No numbers read from the abstract.